Weekly Research Analysts’ Ratings Updates for Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (NASDAQ: SUPN) recently received a number of ratings updates from brokerages and research firms:

• 12/19/2025 – Supernus Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $50.00 to $55.00. They now have a “hold” rating on the stock.
• 12/15/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Supernus Pharmaceuticals was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/1/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Supernus Pharmaceuticals had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Supernus Pharmaceuticals was downgraded by analysts at Weiss Ratings from a “hold (c+)” rating to a “sell (d+)” rating.
• 11/8/2025 – Supernus Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.
• 10/29/2025 – Supernus Pharmaceuticals is now covered by analysts at Bank of America Corporation. They set a “buy” rating and a $65.00 price target on the stock.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. This represents a 56.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total value of $31,552.40. Following the completion of the transaction, the vice president owned 14,508 shares in the company, valued at $644,735.52. The trade was a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 90,845 shares of company stock valued at $4,560,380. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.